Table of contents

Papers

• Supplement: Evidence for microRNA-mediated regulation in rheumatic diseases (7 December, 2009)

  X Luo, L M Tsai, N Shen, D Yu
• Supplement: Does gene expression analysis inform us in rheumatoid arthritis? (7 December, 2009)

  T Häupl, B Stuhlmüller, A Grützkau, A Radbruch, G-R Burmester
• Supplement: Role of interleukin 33 in human immunopathology (7 December, 2009)

  G E J Murphy, D Xu, F Y Liew, I B McInnes
• Supplement: Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies (7 December, 2009)

  J H W Distler, O Distler
• Supplement: What are the new milestones in the pathogenesis of systemic sclerosis? (7 December, 2009)

  N Hunzelmann, J Brinckmann
• Supplement: Inflammation, vascular injury and repair in rheumatoid arthritis (7 December, 2009)

  A J van Zonneveld, H C de Boer, E P van der Veer, T J Rabelink
• Supplement: Heart disease and rheumatoid arthritis: understanding the risks (7 December, 2009)

  S E Gabriel
• Supplement: Treg and lupus (7 December, 2009)

  M Bonelli, J S Smolen, C Scheinecker
• Supplement: XBP1: the last two decades (7 December, 2009)

  L H Glimcher
• Supplement: Can we prevent immunogenicity of human protein drugs? (7 December, 2009)

  D W Scott, A S De Groot
• Supplement: “Go upstream, young man”: lessons learned from the p38 saga (7 December, 2009)

  D Hammaker, G S Firestein
• Supplement: The role of cell–substrate interaction in regulating osteoclast activation: potential implications in targeting bone loss in rheumatoid arthritis (7 December, 2009)

  K P McHugh, Z Shen, T N Crotti, M R Flannery, R P O’Sullivan, P E Purdue, S R Goldring
• Supplement: Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun) (7 December, 2009)

  E F Wagner
• Supplement: The value of productivity: human-capital versus friction-cost method (7 December, 2009)

  W B van den Hout
• Supplement: The pro and anti-inflammatory activities of immunoglobulin G (7 December, 2009)

  A Lux, S Aschermann, M Biburger, F Nimmerjahn
• Supplement: What have we learnt from targeted anti-TNF therapy? (7 December, 2009)

  M Feldmann, R O Williams, E Paleolog